Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Carnivale

Internal Medicine Pittsburgh, PA Medical Doctor

NPI 1366472573 CMS profile 243597

3720 Brownsville Rd, Pittsburgh, PA 15227

Open in the dashboard

General payments

$19,199

1,116 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Carnivale of Pittsburgh, PA is reported in the CMS Open Payments database as having received $19,199 across 1,116 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,630 128
2024 General $3,037 165
2023 General $3,343 184
2022 General $3,100 177
2021 General $2,854 175
2020 General $2,159 138
2019 General $2,077 149

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Carnivale
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Scott Carnivale were reported at $2,630. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Scott Carnivale Internal Medicine median Middle half National median
2019 $2,077 $159 $48–$570 $163
2020 $2,159 $119 $33–$402 $114
2021 $2,854 $135 $37–$521 $132
2022 $3,100 $141 $42–$496 $149
2023 $3,343 $149 $45–$519 $160
2024 $3,037 $154 $47–$537 $164
2025 $2,630 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,301 134 payments
  2. Novo Nordisk Inc $2,141 120 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,947 120 payments
  4. Pfizer Inc. $1,938 130 payments
  5. Lilly USA, LLC $1,662 98 payments
  6. Janssen Pharmaceuticals, Inc $1,514 91 payments
  7. AbbVie, Inc. $1,198 62 payments
  8. AstraZeneca Pharmaceuticals LP $1,123 64 payments
  9. Merck Sharp & Dohme Corporation $759 39 payments
  10. Sanofi-Aventis U.S. LLC $687 49 payments
  11. Other $3,928 209 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $19,139 1,109 payments
  2. Education $60 7 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,654 95 payments
  2. ELIQUIS $1,212 82 payments
  3. Ozempic $1,186 66 payments
  4. JARDIANCE $1,034 63 payments
  5. RYBELSUS $931 51 payments
  6. XARELTO $800 53 payments
  7. NURTEC ODT $785 48 payments
  8. MOUNJARO $725 41 payments
  9. SPRAVATO $709 37 payments
  10. FARXIGA $656 36 payments
  11. Other $16,333 968 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 158 drugs

Part D claims

12,328

Median for Internal Medicine: 777

Drug cost

$955,712

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 156 $146,249
Jardiance Empagliflozin Brand 155 $142,906
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 139 $105,568
Xarelto Rivaroxaban Brand 105 $77,181
Ozempic Semaglutide Brand 61 $57,131
Farxiga Dapagliflozin Propanediol Brand 84 $50,033
Rybelsus Semaglutide Brand 52 $48,821
Tradjenta Linagliptin Brand 31 $30,647
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 22 $26,166
Myrbetriq Mirabegron Brand 33 $25,579

The 10 drugs with the highest cost, of 158 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$94,766

Of which drugs: $11,054

Medicare patients

291

Average age 73

Services billed

1,626

158 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 45%
Diabetes 22%
Ischemic heart disease 19%
Osteoporosis 19%
Chronic kidney disease 14%
Atrial fibrillation 13%
COPD 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 79 79 $6,382
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 11 11 $1,439
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 41 41 $898

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 39 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
$265 139 —
JARDIANCE
$263 155 —
SPRAVATO
$255 — —
AIRSUPRA
$188 — —
MOUNJARO
$144 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 39 with Patron

Records

1,116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record